Odyssey Therapeutics, Inc. Financing Cash Flow
Odyssey Therapeutics, Inc. (ODTX) reported Financing Cash Flow of $292.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Odyssey Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $292.16M, a 146.09% increase year-over-year.
- Odyssey Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $484.00K, a 142.00% increase year-over-year.
- Odyssey Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $118.72M.
- Odyssey Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $200.00K.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month |
|---|---|---|
| 2026-06-30 | $292.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $292.64M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $484.00K 10-Q · filed 2026-06-17 | |
| 2025-06-30 | $118.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $118.92M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $200.00K 10-Q · filed 2026-06-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |